ArticleKidney medicine2025
Plasma and Urine Metabolites Associated With Nondiabetic Chronic Kidney Disease: The HELIUS Study.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.Kidney international reports · 2026Review
- Urinary Microcholesterol and Adverse Kidney Outcomes in CKD.Kidney international reports · 2026Article
- Association between volatile organic compounds in urine and dyslipidemia: findings based on analysis of NHANES data.Lipids in health and disease · 2025Article
- Optimised RFO tuned RF-DETR model for precision urine microscopy for renal and systemic disease diagnosis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: We aimed to find predictive plasma and urine metabolites for nondiabetic chronic kidney disease (CKD), and to validate these biomarkers in a diabetic kidney disease (DKD) population, using data of the population-based multiethnic Healthy Life in an Urban Setting study. Study Design: Cross-sectional metabolome study. Setting & Participants: From the Healthy Life in an Urban Setting population-based cohort, we included 124 participants with nondiabetic CKD, 45 with DKD and 200 healthy controls. Predictors: Plasma and urine metabolites were measured using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) with an untargeted approach. Outcomes: (Nondiabetic) CKD. Analytical Approach: We used machine learning models to predict nondiabetic CKD from metabolite profiles and used logistic regression models with adjustment for potential confounders to verify our results in the best predicting metabolites. In addition, we assessed the associations between the best predicting metabolites and DKD. Results: Urine metabolites were more predictive of nondiabetic kidney disease than plasma metabolites. In plasma, the best predicting metabolites for nondiabetic CKD included many amino acids, including N-acetylated amino acids, histidine, and indolepropionate. In urine, the highest-ranked metabolites were predominantly lipids, including sphingomyelins and phosphatidylcholines. There was limited overlap among the top-ranked metabolites in predicting nondiabetic CKD between plasma and urine. Almost all associations with nondiabetic CKD could be translated to DKD. No interactions were observed with ethnicity. Limitations: The cross-sectional design limits causal inference. Conclusions: Our analyses revealed that urine metabolites were strongly associated with CKD than plasma metabolites in this multiethnic population. The finding that specific associations of plasma and urine metabolites could be translated to subjects with DKD suggests a shared pathophysiological background.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.